The study by Anagnostou et al. consisted of a cohort of metastatic melanoma patients either receiving anti-PD1 blockade alone, or anti-CTLA4 and anti-PD1 blockade in combination (72). The gene discussed is CTLA4; the disease is metastatic melanoma.